Additional Proxy Soliciting Materials (definitive) (defa14a)
April 20 2023 - 7:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.__)
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| |
☐ | Preliminary Proxy Statement |
☐ | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ | Definitive Proxy Statement |
☒ | Definitive Additional Materials |
☐ | Soliciting Material Under §240.14a-12 |
| | |
Aclaris Therapeutics, Inc. |
(Name of Registrant as Specified In Its Charter) |
| | |
| | |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | |
| | |
Payment of Filing Fee (Check all boxes that apply): |
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
| Your Vote Counts!
ACLARIS THERAPEUTICS, INC.
C/O BROADRIDGE
P.O. BOX 1342
BRENTWOOD, NY 11717
ACLARIS THERAPEUTICS, INC.
2023 Annual Meeting
Vote by May 31, 2023
11:59 PM ET
You invested in ACLARIS THERAPEUTICS, INC. and it’s time to vote!
You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the
availability of proxy material for the stockholder meeting to be held on June 1, 2023.
Vote Virtually at the Meeting*
June 1, 2023
9:00 AM, Eastern Time
Virtually at:
www.virtualshareholdermeeting.com/ACRS2023
*Please check the meeting materials for any special requirements for meeting attendance.
Smartphone users
Point your camera here and
vote without entering a
control number
V1.1
For complete information and to vote, visit www.ProxyVote.com
Control #
V04639-P91321
Get informed before you vote
View the Notice and Proxy Statement and 2022 Annual Report online OR you can receive a free paper or email copy of the material(s)
by requesting prior to May 18, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder
meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com.
If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not
otherwise receive a paper or email copy. |
| THIS IS NOT A VOTABLE BALLOT
This is an overview of the proposals being presented at the
upcoming stockholder meeting. Please follow the instructions on
the reverse side to vote these important matters.
Vote at www.ProxyVote.com
Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.
Voting Items
Board
Recommends
V04640-P91321
01) Anand Mehra, M.D.
02) Andrew Powell, Esq.
03) Maxine Gowen, Ph.D.
1. Election of Directors
Nominees:
2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement
accompanying the proxy card.
3. To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized
number of shares of common stock from 100,000,000 shares to 200,000,000 shares.
4. To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the
independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2023.
NOTE: Such other business as may properly come before the meeting or any adjournment thereof.
For
For
For
For |
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024